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Abstract
Introduction: Interferon regulatory factor 5 gene (IRF5) polymorphisms are strongly associated with several diseases,
including systemic lupus erythematosus (SLE). The association includes risk and protective components. They could be
due to combinations of functional polymorphisms and related to cis-regulation of IRF5 expression, but their mechanisms
are still uncertain. We hypothesised that thorough testing of the relationships between IRF5 polymorphisms, expression
data from multiple experiments and SLE-associated haplotypes might provide useful new information.
Methods: Expression data from four published microarray hybridisation experiments with lymphoblastoid cell lines
(57 to 181 cell lines) were retrieved. Genotypes of 109 IRF5 polymorphisms, including four known functional
polymorphisms, were considered. The best linear regression models accounting for the IRF5 expression data were
selected by using a forward entry procedure. SLE-associated IRF5 haplotypes were correlated with the expression
data and with the best cis-regulatory models.
Results: A large fraction of variability in IRF5 expression was accounted for by linear regression models with IRF5
polymorphisms, but at a different level in each expression data set. Also, the best models from each expression data set
were different, although there was overlap between them. The SNP introducing an early polyadenylation signal,
rs10954213, was included in the best models for two of the expression data sets and in good models for the other two
data sets. The SLE risk haplotype was associated with high IRF5 expression in the four expression data sets. However,
there was also a trend towards high IRF5 expression with some protective and neutral haplotypes, and the protective
haplotypes were not associated with IRF5 expression. As a consequence, correlation between the cis-regulatory best
models and SLE-associated haplotypes, regarding either the risk or protective component, was poor.
Conclusions: Our analysis indicates that although the SLE risk haplotype of IRF5 is associated with high expression
of the gene, cis-regulation of IRF5 expression is not enough to fully account for IRF5 association with SLE
susceptibility, which indicates the need to identify additional functional changes in this gene.
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Systemic lupus erythematosus (SLE) [1-4], Sjögren’s
syndrome [5-7], systemic sclerosis [8-11] and primary
biliary cirrhosis [12,13] are complex autoimmune dis-
eases with a genetic component that includes among
their strongest susceptibility loci the interferon regula-
tory factor 5 gene (IRF5). There are reports indicating
that this gene can be associated with a subgroup of
patients with rheumatoid arthritis [14-16] and patients
with other autoimmune diseases [17-19]. The IRF5 gene
encodes a transcription factor involved in the innate
immune response as part of the type I IFN pathway,
and its risk alleles have been associated with increased
expression of this pathway [20,21]. Multiple polymorph-
isms in IRF5 are associated with disease susceptibility,
b u ti ti su n c l e a rw h i c ho ft h e mi sc a u s a la n dh o wt h e s e
polymorphisms contribute to disease predisposition.
This uncertainty is a serious obstacle to progress in
these complex diseases.
Four polymorphisms with a putative functional role
have been described. One of them is an insertion-dele-
tion polymorphism (indel) changing 10 amino acids in
exon 6, but experimental evidence of any effect asso-
ciated with this indel is still lacking [22,23]. The other
three polymorphisms are involved in processes that
could influence expression levels of IRF5.T h eTa l l e l e
of rs2004640 introduces a donor splice site that
exchanges alternative first exons. It could affect levels of
IRF5 mRNA through differences in cis-regulation [2],
but its relevance has been questioned [22]. The CGGGG
indel modulates binding of the Sp1 transcription factor
in the IRF5 promoter [24], but it did not contribute
independently to IRF5 levels in a study involving blood
cells from healthy controls [25]. The strongest evidence
of a role in cis-regulation has been found for the
remaining functional polymorphism, rs10954213. Its A
allele creates an early polyadenylation site that leads to a
shorter mRNA isoform with an extended half-life and
higher IRF5 expression in both lymphoblastoid cell lines
(LCLs) [3,23] and blood cells [25]. However, according
to studies done with LCLs, this SNP is not enough to
fully account for IRF5 cis-regulation [3,23]. In addition,
researchers in a study analysing IRF5 expression in
blood cells from SLE patients did not find any signifi-
cant effect of this SNP or of any of the functional
polymorphisms [26]. These contrasting pieces of evidence
do not allow for a clear understanding of IRF5 cis-regula-
tion and its relationship to disease susceptibility.
IRF5-dependent disease susceptibility is determined by
haplotypes with opposed effects: risk and protection
[3-5,11,15,16,22,23]. The risk haplotype, identified by
the rare allele of rs10488631 (or rs2070197), could be
due to a combination of effects of the known functional
polymorphisms, but its components are unclear. It has
been proposed to result from the combination of two
functional polymorphisms, rs2004640 and rs10954213,
and a SNP of unknown relevance [3], or from a gradation
of the effects of three functional polymorphisms, the two
mentioned plus the exon 6 indel [23], or from an epi-
static interaction between a unique combination of alleles
at the same three functional polymorphisms [4]. Other
s t u d i e sh a v el e f tt h i sm a t t e rm o r eo rl e s su n d e f i n e d
because of the lack of convincing evidence of the rele-
vance of all the polymorphisms’ segregating with the risk
haplotype [22], or they have proposed, after the discovery
of the CGGGG indel, that this functional polymorphism
determines SLE increased risk together with not yet
known functional polymorphisms [24]. The protective
haplotypes are represented by the rare allele of rs729302
that is 5’ to the gene, but are not correlated with any of
the functional polymorphisms [3,4,23]. Therefore, none
of the two effects has a clear relationship to known func-
tional polymorphisms or to IRF5 function.
Here we address these questions using, for the first time,
information from multiple mRNA expression studies and
from the four known functional IRF5 polymorphisms.
This approach allowed us to assess the reproducibility and
generality of the results. Also, it afforded us the opportu-
nity to test the independent contribution of each
functional polymorphism and to identify the SNP introdu-
cing an early polyadenylation signal, rs10954213, as the
clearest cis-regulatory one. In addition, we have confirmed
that the SLE risk haplotype is associated with high IRF5
expression. However, the lack of correlations between
cis-regulatory polymorphisms and SLE association and
between IRF5 expression and SLE protective haplotypes
indicates that SLE association involves changes in IRF5
function apart from its expression.
Materials and methods
Lymphoblastoid cell line expression data
IRF5 expression data from two collections of LCLs were
obtained from four published microarray studies
(Table 1). Three of the studies were done with LCLs
from unrelated subjects derived from the European
population from the International HapMap Project
(CEU) [27-29], which lacks significant admixture and
has been used as the reference for the European Cauca-
sian population in many studies. The fourth study was
done with LCLs from children with asthma [30]. That
study included 206 UK families with negligible popula-
tion stratification. We have used only the LCLs from
each family having the best genotype call rate, leaving
us with a total of 181. Data were obtained from the
Gene Expression Omnibus repository [27,28] (accession
numbers GSE6536 and GSE2552) or from the study
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that included a variety of probes to examine IRF5
expression (Figure 1). We used expression data only
from validated probes in each study.
IRF5 genotypes of the lymphoblastoid cell line
The linkage disequilibrium (LD) block encompassing
IRF5 was defined according to International HapMap
Project data on the CEU population between 128,158 kb
and 128,304 kb on chromosome 7 (HapMap Rel 21a/
p h a s eI IJ a n 0 7 ,N C B IB 3 5 ,d bSNPb125). Genotypes of
the CEU LCLs for the 72 SNPs included in this 146-kb
region (Additional file 1, Table S1) were downloaded
from the International HapMap Project (HapMap) [31].
Data from 27 SNPs in this LD block were available in
the asthma collection of LCLs.
Table 1 Expression profiling studies in lymphoblastoid cell lines whose IRF5 data have been analysed
a
Study Number of
LCLs
Microarray system used Number of IRF5 probes
used
LCL collection
group
Kwan et al. [29] 57 GeneChip Human Exon 1.0 ST Array (Affymetrix, Inc.) 17 CEU
Stranger et al. [28] 60 Illumina WG-6v1 BeadChip Array (Illumina, Inc.) 2 CEU
Cheung et al. [27] 58 GeneChip Human Genome Focus Array (Affymetrix, Inc.) 1 CEU
Dixon et al. [30] 181
b GeneChip Human Genome U133 Plus 2.0 Array
(Affymetrix, Inc.)
3 Asthma
aIRF5 = interferon regulatory factor 5 gene; LCL = lymphoblastoid cell line; CEU = European population from International HapMap Project database;
bnumber of
LCLs selected for having the best genotyping call rate per family among the 400 LCLs available.
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Figure 1 Map of IRF5 locus. Positions of relevant polymorphisms and of the probes included in each of the four microarray studies are
indicated. Probes are colour-coded according to their reference source: light grey, Kwan et al. [29]; black, Stranger et al. [28]; striped pattern,
Cheung et al. [27]; white, Dixon et al. [30].
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We obtained complete genotype information in the IRF5
LD block to a total of 109 polymorphisms (Additional
file 1, Table S1) by imputation using MACH 1.0 soft-
ware [32]. Information for imputation was taken from
three sources: the 72 SNPs that had been studied in
HapMap LCLs, the 27 SNPs available in the asthma
LCLs and the 56 SNPs that we have genotyped in 95
healthy Spanish donors. In this way, it was possible to
include the four putative functional polymorphisms
(absent from HapMap) and more SNPs in the 5’ region
of IRF5 (seven SNPs in tight LD with rs729302, the tag-
ging SNP for the protector haplotypes in SLE) (Addi-
tional file 2, Figures S1 and S2). There were overlaps
between the HapMap and asthma data sets (21 SNPs)
and between HapMap and the Spanish donors (nine
tagging SNPs). Genotypes of the Spanish donors were
obtained by using the ABI PRISM SNaPshot Multiplex
K i t( A p p l i e dB i o s y s t e m s, Carlsbad, CA, USA) as
described previously [4], except for rs3778752, rs3778751
and the CGGGG indel, which were sequenced (Addi-
tional file 1, Tables S2 and S3), and the exon 6 indel that
was genotyped by length variation in agarose electro-
phoresis as described previously [4]. Polymorphisms with
a MACH 1.0 quality score < 0.8 were discarded.
DNA samples from controls were obtained with their
informed written consent, and the study was approved
by the Committee for Clinical Research of Galicia
(Spain).
Statistical analysis
Expression results from probes targeting introns were
excluded from the analysis. Expression data were trans-
formed into standardised normal distributions (that is,
expression data from each probe were transformed into
new variables with mean = 0 and standard deviation = 1
by subtracting the mean to each value and dividing the
result by the standard deviation) to avoid differences in
scale when performing comparisons between studies.
Relations of the expression results with the IRF5 poly-
m o r p h i s m sw e r ea n a l y s e db ym ultiple linear regression.
These analyses were performed with a forward entry pro-
cedure, which adds new polymorphisms to the regression
model one-by-one, starting with the most associated
until no further significanti m p r o v e m e n ti sa c h i e v e do r
until one of the polymorphisms does not show a signifi-
cant contribution to the model. A genetic additive model
(with values 0, 1 and 2 for the AA, Aa and aa genotypes,
respectively) was considered. Only one of each pair of
polymorphisms, to a total of 35 polymorphisms, with r
2 ≥
0.90 was included in the analyses to avoid collinearity
problems (Additional file 1, Table S1). Nested linear
regression models were compared using the likelihood
ratio test. Nonnested models were compared using
Davidson and MacKinnon’s J-test [33], which specifies a
proxy parameter in an artificial nested model combining
the two nonnested models and then tests the proxy
parameter. All analyses wered o n eu s i n gS t a t i s t i c a7 . 0
software (StatSoft, Tulsa, OK, USA) or in R software
implementations, except for haplotype estimation, which
was done using Phase 2 software [34].
Results
IRF5 expression in lymphoblastoid cell lines
To ascertain cis-regulatory IRF5 polymorphisms, we
selected four studies (Table 1) containing IRF5 genotypes
and microarray expression data in LCLs [27-30]. The mul-
tiplicity of studies and hybridisation probes (Figure 1)
allowed us to select the most representative expression
results. As a first step in this process, we used the study by
Kwan et al. [29], which included 13 probes targeting
specific IRF5 exons in LCLs from the CEU population of
HapMap. Two different groups of results were identified
(Figure 2). The first group included eight probes that were
highly correlated (mean pairwise r
2 = 0.79). They hybri-
dised with exons 2, 3, 5, 6 (not including the 30-bp indel),
7, 8 and 9 and with the 3’UTR previous to the early polya-
denylation signal SNP rs10954213. The uncorrelated
results were obtained with probes hybridising with exons
1A and 1C, which are alternatively spliced and untrans-
lated; with exon 4, which is the smallest; and with the
sequence of exon 6, which is present only in splice variant
5. We took the average of the first group as representative
of IRF5 expression and named it K8.
The other two microarray studies done with CEU
LCLs contained fewer IRF5 probes. The Stranger et al.
study [28] included probes hybridising with exon 1A
and with the 3’UTR previous to rs10954213 (Figure 1).
Only results from the second probe correlated with K8
(r
2 = 0.56), and they were taken as representative and
called S (Figure 2). The Cheung et al.s t u d y[ 2 7 ]
included only one IRF5 probe (Figure 1), which hybri-
dised with the upstream region of exon 9 and the
3’UTR. The results of this probe, which we identified
as C, strongly correlated with the results for K8 (r
2 =
0.60) and S (r
2 = 0.75) (Figure 2). The high correlation
between the three data sets, K8, S and C, permitted us
to obtain a global average that was denoted KSC. For an
analysis of the unselected data, see Additional file 2,
Supplementary Information.
To increase the generality of the results, we used a
fourth study that had examined a different collection of
LCLs [30]. That study included data derived from three
IRF5 probes (Figure 1), which were poorly correlated
(not shown). We considered as representative only the
probe that was shared with the study by Cheung et al.
[27] and targeted sequences addressed in the other two
studies. These data were named D.
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The forward entry multiple linear regression process led to
the identification of four best models, one for each of the
data sets and a best model for the KSC average that
included the same polymorphisms as the best model for S.
The best model for the K8 results, which included geno-
types at two SNPs, rs3807306 and rs17424179 (Table 2),
explained 0.31 of the variance in IRF5 expression. The first
SNP, rs3807306, is in IRF5 intron 1 and is the most
associated in the model. This SNP showed an r
2 value lar-
ger than 0.7 with 22 polymorphisms, including two func-
tional ones: rs10954213 (r
2 = 0.79) and the CGGGG indel
(r
2 = 0.75). The second SNP, rs17424179, is 68 kb 3’ to
IRF5. It did not show a strong correlation with any other
polymorphism (all pairwise r
2 < 0.2). Its contribution to
the model fit was small. The best model for S results
included three SNPs that accounted for a very large frac-
tion of variability in IRF5 expression (adjusted r
2 =0 . 8 0 ) .
The strongest association in this model was with
rs10954213 (Table 2). The two other SNPs were the same
as the best model for K8, rs3807306 and rs17424179. The
best model for the C expression data also accounted for a
large fraction of variability (adjusted r
2 = 0.55), including
only two SNPs (Table 2). The major contribution corre-
sponded to rs2280714, which is 4.6 kb 3’ to IRF5 and
showed a strong correlation with the second SNP in
the model, rs10954213 (r
2 = 0.84), and with 25 other SNPs
(r
2 > 0.7). As this model includes two highly correlated
SNPs, their independent contributions were severely
reduced in relation to the model fit (P = 0.02 for each of
the two SNPs in a model with P = 9.2 × 10
-11). As a form
of summary of these three data sets, the average KSC

Figure 2 Correlation between IRF5 expression results obtained with different probes and in different experiments. Only results obtained
with the same European population from the International HapMap Project (CEU) lymphoblastoid cell line (LCL) are compared. Bidimensional,
nonparametric, multidimensional scaling was used for representation. Data from probes selected as representative are within the dashed circle.
Labels for data from each probe indicate the number of the exon they target, including the 1A and 1C alternative exons and a variant sequence
of exon 6 (6_v5), and UTR-pre and UTR-pro for the probes targeting the 3’UTR previous or posterior to rs10954213, respectively. Filled circles
correspond to data from Kwan et al. [29], empty circles correspond to data from Stranger et al. [28] and empty squares correspond to data from
Cheung et al. [27].
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accounted for (66% of the variability) by a best model with
three SNPs that were the same and in the same order as
those in the best model for S data (Table 2). Therefore,
the three studies with the same cell lines showed expres-
sion data that could be largely explained by cis-regulation
because of a small number of polymorphisms.
The best model for the independent D results com-
prised two polymorphisms: the functional CGGGG indel
and the already mentioned rs2280714 (Table 2), which
is strongly correlated with rs10954213, among others.
The polymorphism composition of the best genetic
models was applied to the other expression data sets to
explore their relationships. The exchanged models were
significantly inferior to the proper best models, with two
exceptions (Figure 3): the model with the best combina-
tion of polymorphisms for the S data set was equivalent
to the best model in the K8 data, which it contained;
and the model with the best combination of polymorph-
isms for the D data set was equivalent to the best model
in the C expression data. The SNP composition
rs10954213, rs3807306 and rs17424179 produced the
best model overall: best for the S data set, not signifi-
cantly different from the best in the K8 data set, second
best for the D data and third best for the C data set. In
addition, it comprised the SNPs in the best model for
the KSC average data.
To ascertain the origin of differences between data
sets, we compared model fit with the scale of expression
levels, the range of values and their dispersion, as well
as with sample size differences, but no correlation was
found. Also, we assessed the best model for K8 in the
results from each of the eight exons in the study by
Kwan et al.[ 3 5 ] .T h ef i to ft h em o d e lr a n g e df r o mr
2 =
0.12 for data from exon 9 and 3’UTR (previous to
rs10954213) to r
2 = 0.37 for data from exon 7 (P = 0.01,
and 1.7 × 10
-6 in linear regression analyses, respectively).
These two exons are shared by all known IRF5 isoforms.
Therefore, these differences point to the probes as the
source of variability because the results are from the
same hybridisation experiment, cancelling all variation
involved in cell culture, mRNA extraction and cDNA
synthesis or labelling. In contrast, data sets C and D
shared the same probe, but they also showed differences
in model fit that should be ascribed, in this case, to other
unidentified factors that could include laboratory proce-
dures and the collection of cells from healthy subjects
and asthma patients in C and D set, respectively.
Role of the putative functional polymorphisms
We have analysed how well models in which only func-
tional polymorphisms were included accounted for the
expression data (Figure 4). Models including the exon 6
indel were clearly inferior and are not shown, given the
lack of any previous evidence of the involvement of the
exon 6 indel in IRF5 cis-regulation. Each of the remain-
ing three functional polymorphisms, considered indivi-
dually, was significantly associated with IRF5 expression
in the four data sets. The early polyadenylation signal
SNP, rs10954213, was clearly dominant among the func-
tional polymorphisms in these individual comparisons,
except in the D data set. However, none of them alone
was able to account for IRF5 expression equivalently to
the proper best genetic model for each data set. Models
combining functional polymorphisms were not better
than models with rs10954213 alone in the three data
Table 2 Best multiple linear regression models with cis-polymorphisms accounting for IRF5 gene expression in each of
the four data sets and in the average expression from CEU LCL (KSC)
a
Best linear regression model Polymorphism P value in model
Data set Adjusted r
2 Model P Polymorphisms
K8 (Kwan et al. [29]) 0.31 1.7 × 10
-5 rs3807306 4.0 × 10
-6
rs17424179 0.026
S (Stranger et al. [28]) 0.80 2.5 × 10
-20 rs10954213 1.2 × 10
-4
rs3807306 2.4 × 10
-3
rs17424179 9.5 × 10
-3
C (Cheung et al. [27]) 0.55 9.2 × 10
-11 rs2280714 0.02
rs10954213 0.02
KSC 0.69 1.3 × 10
-13 rs10954213 5.1 × 10
-3
rs3807306 0.013
rs17424179 0.011
D (Dixon et al. [30]) 0.28 1.3 × 10
-13 CGGGG indel 2.4 × 10
-6
rs2280714 8.3 × 10
-4
aIRF5 = interferon regulatory factor 5 gene; LCL = lymphoblastoid cell line; CEU = European population from International HapMap Project database; KSC =
average of standard normal transformed K8, S and C data. Statistical parameters of the best models are provided together with P values corresponding to
independent contribution of each polymorphism to the model. Data sets in left column are representative IRF5 expression results.
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models including rs10954213, together with rs2004640
or with the CGGGG indel, were the best in accounting
for the D expression data and were not inferior to the
proper best model. It is important to note that in these
two models and in this data set, the two component
polymorphisms showed a significant independent contri-
bution (Additional file 2, Table S1). In the other three
data sets (K8, S and C), the best models with two
functional polymorphisms included rs10954213 with
rs2004640 and, immediately below, rs10954213 with the
CGGGG indel. Only rs10954213, however, showed a
significant independent contribution in these combined
models (Additional file 2, Table S1).
A search for other putative functional polymorphisms
in the IRF5 sequence with two bioinformatics applica-
tions, Pupasuite 3.1 [36] and FastSNP [37], gave only an
SNP that could introduce an alternative splice site in
intron 1, but it was not polymorphic in our 95 Spanish
samples.
Relationship between IRF5 expression and systemic lupus
erythematosus susceptibility
We used haplotypes defined in previous reports to
assess the relationship between IRF5 expression and SLE
susceptibility [2,4] (Additional file 2, Table S2). The SLE
risk haplotype H6 is identified by the minor allele of
rs10488631. The protective haplotypes H1 and H2 are
defined by the minor allele of rs729302, with H1 includ-
ing the A allele of rs10954213 and H2 including the G
allele. They share the minor allele of rs2004640 with the
neutral haplotype H3, but this latter haplotype lacks the
minor allele of rs729302. H4 and H5, which are SLE-
neutral, are very similar to the risk haplotype H6 but


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



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


Figure 3 Cross-check analysis of the best linear regression genetic models. Polymorphism composition of each of the best models from
Table 2 was applied to the four expression data sets and the -log10 P values for their fit are represented. Models defined as best in expression
data sets with CEU LCL are shown in black (triangles for K8, squares for S and circles for C), and the best model defined with asthma cell lines in
D is presented as white squares. Expression data sets labels in the X-axis are as in Table 2. Comparisons with the proper best model for each
data set were either nonsignificantly inferior (n.s.) or inferior with *P < 0.05, **P < 0.01 or ***P < 0.001.
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models for any of the expression data sets was strongly
correlated (all r
2 ≤ 0.15) with the haplotypes defining
SLE risk (H6) or SLE protection (H1 and H2) (Addi-
tional file 2, Table S3). However, we found that the
minor allele of rs10488631 that identifies the SLE risk
haplotype was significantly associated with increased
IRF5 expression in all data sets (all P <0 . 0 0 9 4 ) .O nt h e
contrary, the minor allele of rs729302 that identifies the
SLE protection haplotype was associated with lower
expression of IRF5 only in the D data set (P =0 . 0 0 2 ) ,
but not in the other data sets (not shown). In addition,
analysis of the association of the estimated haplotypes
showed that the only haplotype consistently associated
with high IRF5 expression in all data sets was the risk
haplotype H6 (Figure 5). However, this finding was not
specific, because there was an association of higher IRF5
expression with neutral haplotypes H4 and H5 in some
data sets. There was also poor correlation between SLE-
protective haplotypes and IRF5 expression. Of the two
protective haplotypes, only the H2 haplotype was consis-
tently associated with lower IRF5 expression (all
P values within the range from 0.009 to 0.0008) (Figure
5). The H1 haplotype was not associated with IRF5
expression in any of the four data sets (all P > 0.09).
Discussion
Identification of SLE causal polymorphisms in IRF5 is
very difficult. A thorough analysis with novel character-
istics including the use of expression data from four
different studies, the inclusion of genotypes of the four
known functional polymorphisms, and the direct
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Figure 4 Evaluation of linear regression models made only of known functional polymorphisms.T h e- l o g 10 P value for the fit of the
models applied to each data set are represented in ordinates and compared with the proper best models (plus signs). Models including only
one of the functional polymorphisms are indicated by filled symbols, and models combining two polymorphisms are shown as open symbols.
Models included either rs10954213 (filled circles), rs2004640 (filled squares), the CGGGG insertion-deletion polymorphism (indel) (filled triangles),
rs10954213 and rs2004640 (open circles), rs10954213 and the CGGGG indel (open squares) or the rs2004640 and the CGGGG indel (open
triangles). Comparisons with the proper best model for each data set were either nonsignificantly inferior (n.s.) or inferior with *P < 0.05,
**P < 0.01, ***P < 0.001 or ****P < 0.0001. Expression data sets in the X-axis are as in Table 2.
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haplotypes and IRF5 expression has provided new and
interesting insights.
The multiplicity of probes and studies allowed us to
select the most representative IRF5 expression data.
They included almost all the probes for IRF5 transcribed
sequences that are common to all isoforms. They
showed good correlation (r
2 ≥ 0.56) between the three
experiments using the same LCLs. However, differences
between experiments led to consequences in the results,
such as with regard to the fraction of expression varia-
bility accounted for by the best cis-regulatory models,
which ranged from 0.28 to 0.80. There is no simple
cause of these differences. They did not correlate with
sample size, with the scale of the expression values or
with their dispersion. However, there were notable
differences within the same experiment that were
dependent on the hybridisation probes. Other undefined
factors, which could include cell culture, sample proces-
sing and differences between cell collections, were also
suggested by our analyses.
Differences between the experiments were also evident
in the best cis-regulatory models. Each expression data
set was best explained by a specific genetic model, but
the polymorphisms included in them were partially
coincident. The best assessment of the relationships
between the four best genetic models was obtained by
applying the models to the other data sets as a sort of
cross-checking procedure (Figure 3). This analysis
showed that it was impossible to identify a single best

Figure 5 Relationship between IRF5 haplotypes and expression in each of the expression data sets. The most common haplotypes of
the interferon regulatory factor 5 (IRF5) gene were defined with eight tag SNPs and from H1 to H6 as described by Ferreiro-Neira et al. [4] (for
haplotype definition, see Supplementary Table 5). H1 and H2 are systemic lupus erythematosus (SLE) protective haplotypes, and H6 is the risk
haplotype. The remaining haplotypes are neutral. Univariate linear regression coefficients with their 95% confidence intervals (95% C.I.) for the
relationship between each haplotype (coded 0, 1 or 2 if absent, heterozygous or homozygous, respectively) and IRF5 expression are shown.
Coefficients significantly larger than 0 (with C.I. not crossing the dashed line at 0) indicate an association with increased IRF5 expression.
Coefficients significantly smaller than 0 show association with decreased IRF5 expression. The values have been rescaled to allow the use of a
single y-axis. Codes for each of the IRF5 expression data sets are given in Table 2.
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Page 9 of 12model explaining IRF5 expression, but it was possible to
define a range of best cis-regulatory models that were
useful for assessing hypotheses.
The multiplicity of best cis-regulatory models makes it
uninteresting to comment on the implications of each.
However, there was a specific combination of SNPs
worth discussing because it was superior to the others
in cross-comparisons. It contained rs10954213 (see next
paragraph) together with rs3807306 and rs17424179
(Figure 3). There has been no previous specific mention
of rs17424179, but rs3807306 has been found to account
for most haplotype effects in SLE association among
African Americans [38], and it has been highlighted
among the IRF5 polymorphisms particularly associated
with multiple sclerosis [18] and rheumatoid arthritis
[14]. In addition, a model with rs3807306 and
rs10954213 was the second best to account for SLE
association in a study in Caucasians [24]. Some of these
associations have been interpreted as if this SNP acted
as a proxy for the CGGGG indel because of LD between
them and lack of an allele-specific effect of rs3807306 in
an electrophoretic mobility shift assay [18,24]. However,
this interpretation is not applicable to our results,
because the indel was also included in the analyses.
Therefore, it is likely that rs3807306 indicates additional
functional polymorphisms or a combination thereof. Its
role in IRF5 cis-regulation is also supported by the ana-
lysis of Rullo et al. [21], in which this SNP showed the
strongest association with IRF5 levels among the 14
SNPs considered, in both the European and the Asian
collections of HapMap LCLs.
The SNP determining early IRF5 polyadenylation,
rs10954213, was clearly dominant in accounting for the
expression data obtained with CEU LCLs (Table 2).
This predominance of rs10954213 in the CEU LCLs was
confirmed in the analyses limited to the known func-
tional polymorphisms (Figure 4). Overall, our analyses
provide strong evidence supporting the role of
rs10954213 in cis-regulating IRF5 expression. They are
compatible with its identification as the main IRF5 cis-
regulatory polymorphism in blood cells from healthy
controls [25] and with previous studies in which its role
and mechanism of action were elucidated [2,3]. How-
ever, Feng et al. [26] recently reported a lack of associa-
tion, a result that could be due to insufficient power
because only 14 to 26 subjects were considered in these
specific comparisons.
The dominant role of rs10954213 in the CEU LCL
data was such that all the genetic models with known
functional polymorphisms were inferior to the model
including only rs10954213. These results suggest that
the other three known functional polymorphisms are
redundant in IRF5 expression. This conclusion should
be tempered by the discordant results obtained with the
asthma LCL expression data. They showed a significant
contribution to the best functional cis-regulatory models
from either rs2004640 or the CGGGG indel in combina-
tion with rs10954213. However, we do not know which
of the results with the two LCL collections is more
representative of the population at large.
We found a consistent association of the SLE risk
haplotype with higher IRF5 expression in the four data
sets (Figure 5). This association has already been
demonstrated in SLE and healthy control blood cells
[25,26]. It has been the focus of attention in previous
r e p o r t sa n di st h eb a s i so ft h eh y p o t h e s i st h a tIRF5
risk alleles act by potentiating the type I IFN pathway.
This hypothesis has received recent experimental
support in studies done with SLE sera [20] and with
LCLs [21].
Our results also indicate that there is more than IRF5
expression in IRF5-dependent disease association. This
was shown by the lack of correlation of the SLE suscept-
ibility haplotypes with the best cis-regulatory models
and with IRF5 expression in either the SLE risk or SLE
protective haplotype. We do not yet have a good
hypothesis of what the additional changes in IRF5,
besides its expression, could be. Possibilities include
alteration of interactions with other proteins, as has
been suggested for the exon 6 indel [22,23], or changes
in the isoforms by alterations in splicing, a mechanism
demonstrated for rs2004640 [2], but with little relevance
[22]. A search for other putative functional polymorph-
isms using bioinformatics tools did not lead us to new
hypotheses. Therefore, the need to continue studying
IRF5 polymorphisms to understand their role in disease
susceptibility is an imperative.
One of the limitations of our study is that only global
IRF5 expression data, as opposed to isoform-specific
data, were obtained from LCLs in basal conditions,
which could be different from the relevant IRF5 isoform,
cell type or activation status. However, it is important to
note that no significant cis-regulation for IRF5 isoforms
has yet been reported, in spite of its many splice var-
iants and their upregulation in SLE [22,26]. In addition,
results with blood cells have been concordant with
results with LCLs [25], and the IRF5 risk haplotype has
also been found to be associated with overexpression of
IRF5 in the blood cells, monocytes and myeloid dendri-
tic cells of SLE patients [26]. An additional limitation
which we acknowledge is the possibility that some of
the best models could be different with the use of actual
genotypes in place of imputed ones. Finally, our study
included only LCLs from European Caucasians. This
was done on purpose because there are differences in
the structure of IRF5 haplotypes and their SLE associa-
tions and differences in IRF5 cis-regulation between
Europeans, Asians and Africans [21,38,39].
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Page 10 of 12Conclusions
Our study has shown significant variability in results
from different studies of IRF5 cis-regulatory polymorph-
isms. However, this variability is compatible with the
finding that cis-regulatory changes in IRF5 expression
are not sufficient to explain their association with SLE,
although there is a consistent association of the SLE risk
haplotype with high IRF5 expression.
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